We first tested if myeloid cell production of TNFα is critical for, and if systemic administration of TNFα can enhance the effect of, an IAP antagonist in treating advanced metastasis from breast cancer, the second leading cause of cancer death in women. Here, TNF is linked to breast carcinoma.